New report published by Global Info Research which offers insights on the global Eosinophilic Esophagitis Drug market.
Eosinophilic esophagitis (EoE, also spelled eosinophilic oesophagitis), also known as allergic oesophagitis, is an allergic inflammatory condition of the esophagus that involves eosinophils, a type of white blood cell. Symptoms are swallowing difficulty, food impaction, vomiting, and heartburn.
Click to view the full report TOC, figure and tables:
Global Eosinophilic Esophagitis Drug Market: Forecast by Type / Application / Region
Eosinophilic esophagitis was first described in children but also occurs in adults. The condition is not well understood, but food allergy may play a significant role. The treatment may consist of removal of known or suspected triggers and medication to suppress the immune response.
The major players in global Eosinophilic Esophagitis Drug market include, AstraZeneca, GSK, Bayer, Adare Pharmaceuticals, DBV Technologies, Dr. Falk Pharma, Quorum Innovations, Shire, Calypso, Celgene and Regeneron.
On the basis of product, the Eosinophilic Esophagitis Drug market is primarily split into, Budesonide, Fluticasone and Others.
On the basis of product pipeline, the Eosinophilic Esophagitis Drug market is primarily split into, APT-1011, Viaskin Milk, Budesonide effervescent tablets, Qi-201, SHP621, CALY-002, RPC4046 and Dupilumab.
In the last several years, global market of eosinophilic esophagitis drug developed smoothly, with an average growth rate of 3.73%. In 2017, global revenue of eosinophilic esophagitis drug is nearly 103 M USD.
The classification of eosinophilic esophagitis drug includes budesonide, fluticasone and other types, and the proportion of budesonide in 2017 is about 52%.
North America is the largest consumption region of eosinophilic esophagitis drug, with a sales market share nearly 32% in 2017. Europe is the second largest consumption region of eosinophilic esophagitis drug, enjoying Sales market share nearly 29% in 2017.
Market competition is intense. AstraZeneca, GSK, Bayer are the leaders of the industry, and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry.
For developing product, there are 2 products in Phase 3; 4 products in Phase 2 and 2 products in Preclinical. SHP621 and Budesonide effervescent tablets are in Phase 3, and they are owned by Dr. Falk Pharma and Shire.
Ask for Discount on Research Report and Request Sample Copy of Report@
GlobalInfoResearch is a report publisher, a customer, interest-based suppliers. Is in the best interests of our clients, they determine our every move. At the same time, we have great respect for the views of customers. With the improvement of the quality of our research, we develop custom interdisciplinary and comprehensive solution. For further development, we will do better and better. GlobalInfoResearch will with excellent professional knowledge and experience to carry out all aspects of our business. At the same time, we will thoroughly look for information, to give a more comprehensive development.
United States Eosinophilic Esophagitis Drug Market 2018 Forecast to 2023
Europe Eosinophilic Esophagitis Drug Market 2018 Forecast to 2023
North America Eosinophilic Esophagitis Drug Market 2018 Forecast to 2023
Asia-Pacific Eosinophilic Esophagitis Drug Market 2018 Forecast to 2023
China Eosinophilic Esophagitis Drug Market 2018 Forecast to 2023
EMEA Eosinophilic Esophagitis Drug Market 2018 Forecast to 2023
Global Eosinophilic Esophagitis Drug Market 2018 Forecast to 2023
Contact US :
Sales Director (Global Info Research)
Tel: +86-13660489451 00852-58197708(HK)
Add: RM 1605C HO KING COMM CTR 2-16 FA YUEN ST MONGKOK KL Hong Kong